Early administration of high-dose antithrombin in severe sepsis: Single center results from the kybersept-trial

Anesthesia and Analgesia

Volumn 107, Issue 5, 2008, Pages 1633-1638

  Eid, Alain ^a   Wiedermann, Christian J ^b   Kinasewitz, Gary T ^c  

^a Division of Pulmonary and Critical Care   (United States)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MALE; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; SEPSIS; TERTIARY HEALTH CARE; TREATMENT DURATION; UNITED STATES; AGED; APACHE; BLOOD PRESSURE; DOSE RESPONSE; HEART RATE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; SURVIVAL; SURVIVOR;

ADULT; AGED; ANTITHROMBINS; APACHE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIPLE ORGAN FAILURE; RISK REDUCTION BEHAVIOR; SEPSIS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 56149089171     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e318184621d     Document Type: Article

References (16)

1. Vincent JL, De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care 2005;9(suppl 4): S9-S12
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
4. Hoffmann JN, Vollmar B, Laschke MW, Fertmann JM, Jauch KW, Menger MD. Microcirculatory alterations in ischemiareperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. Crit Care 2005;9(suppl 4):S33-S37
5. Hoffmann JN, Vollmar B, Romisch J, Inthorn D, Schildberg FW, Menger MD. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002;30:218-25
6. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78
7. LaRosa SP, Opal SM. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005;21:433-48
8. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63
9. Le Gall JR, Lemeshow S, Leleu G, Klar J, Huillard J, Rue M, Teres D, Artigas A. Customized probability models for early severe sepsis in adult intensive care patients. Intensive Care Unit Scoring Group. JAMA 1995;273:644-50
10. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke H-O, Warren BL, Opal SM, for the KyberSept investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006;34:285-92
11. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke H-O, Warren BL, Opal SM, for the KyberSept investigators. Treatment effects of highdose antithrombin III without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-7
12. Hoffmann JN, Muhlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004;32:1851-9
13. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997;8:328-34
14. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41
15. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM; KyberSept investigators. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95:850-6
16. Wiedermann CJ, Keinecke HO, Jü rs M, Opal SM. Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants. Shock 2006; 25:657-8